31 August 2022 - NICE has published evidence-based recommendations on the use of brolucizumab (Beovu) for the treatment of adults with diabetic macular oedema.

Brolucizumab is recommended as an option for treating visual impairment due to diabetic macular oedema in adults, only if:

• the eye has a central retinal thickness of 400 micrometres or more at the start of treatment
• Novartis provides brolucizumab according to the commercial arrangement

Read NICE Technology Appraisal Guidance